Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
The mucormycosis is also known as black fungus. It is a serious fungal infection which is caused to peoples whose having reduced ability to fight with infections. Symptoms of the mucormycosis depends on where in the body the infection occurs. It mostly infects the nose, sinuses, eye and brain resulting in a runny nose, one sided facial swelling and pain, headache, fever, blurred vision, swollen and bulging eye and tissue death. Other forms of diseases may infect the lungs, stomach and intestines and skin. It is spread by spores of molds of the order Mucorales, most often through inhalation, contaminated food or contamination of open wounds.
The Europe mucormycosis market is witnessing lucrative growth during forecast period of 2021 to 2027. The fungi are common in soils, decomposing organic matter like rotting fruit and vegetables and animal manure but they generally not affect the peoples. It is not transmitted between the peoples. The key factors such as emergence of COVID-19 patients is propelling growth of Europe mucormycosis market. The increasing cases of blood cancers and diabetes is also boosting growth of Europe mucormycosis market. The weak immune systems due to high blood sugar levels is also refuelling growth of Europe mucormycosis market. However, side effects of drugs is also boosting growth of Europe mucormycosis market.
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 3600 analysis of micro and macro-economic factors on the mucormycosis market. In addition, complete analysis of changes on mucormycosis expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on Europe economies, international trade, business investments, GDP and marketing strategies of key players present in the market. The COVID-19 has almost affected every market is healthcare industries positively or negatively. The mucormycosis market is primarily driven by the emergence of COVID-19 pandemics. Before the pandemic situation, the fungal infection is rare but COVID-19 is causing high healthcare challenges across the globe. The increasing cases of COVID-19 will significantly increase the number of mucormycosis cases across the globe.
The Europe mucormycosis market is categorised into the species, diagnosis method, drugs, distribution channel and country.
Based on species, the Europe mucormycosis market is segmented into the rhizopus, cuninghamella, rhizomucor, saksenaea, apophysomyces, lichtheimia, mucor and other species. In which rhizomucor is also contributing to the growth of Europe mucormycosis market. The rhizomucor is a genus of fungi in the family lictheimiaceae. The widespread genus contains six species. The rhizomucor is distinguished from mucor by the presence of stolons and poorly developed rhizois at the base of the sporangiophores and by thermophilic nature of the species.
Based on diagnosis methods, the Europe mucormycosis market is bifurcated into the magnetic resonance imaging, computed tomography, tissue biopsy and others. The tissue biopsy is also contributing to the growth of Europe mucormycosis market. The rising technological advancement is healthcare industry is propelling growth of Europe mucormycosis market. The growing prevalence of COVID-19 diseases is also boosting growth of Europe mucormycosis market.
Based on drugs, the Europe mucormycosis market is categorised into the Amphotericin B, isavuconazole, Posaconazole, voriconazole, flucytosine, fluconazole and other drugs. The fluconazole is also contributing to the growth of Europe mucormycosis market. The growing diseases affecting immune systems is propelling growth of Europe mucormycosis market. The growing research and development activities is also boosting growth of Europe mucormycosis market.
Based on distribution channel, the Europe mucormycosis market is segmented into the hospital pharmacies, retail pharmacies and online pharmacies. The online pharmacies is also contributing to the growth of Europe mucormycosis market. The rising offering of services and discounts offered by online pharmacies is propelling growth of the Europe mucormycosis market. The growing prevalence of mucormycosis is also boosting growth of Europe mucormycosis market.
The Europe mucormycosis market is studied for key countries such as United Kingdom, Germany, France, Italy and Spain. In which United Kingdom is anticipated to dominate the market in 2020. The rising disposable income is propelling growth of Europe mucormycosis market. The rising healthcare facilities is also boosting growth of Europe mucormycosis market. The growing prevalence of COVID-19 is also driving growth of Europe mucormycosis market.
The major key players such as Natco Pharmaceuticals, Alembic Pharmaceuticals, Gufic Biosciences, Lyca Pharmaceuticals, Emcure Pharmaceuticals, Bharat Serums And Vaccines, Bdr Pharmaceuticals, Cipla Limited, Lifecare Innovations, Synbiotics Limited, Kamla Lifesciences, Cadila Healthcare Limited and Tlc Pharma Labs among others.
June 2021: Celon Laboratories launched an alternative drug, Amphotericin B Emulsion for the treatment of mucormycosis.
May 2021: TLC Pharma, a clinical-stage specialty pharmaceutical company, received approval for the New Drug Application (NDA) for Amphotericin B liposome injection (AmphoTLC), form the Central Drugs Standard Control Organization (CDSCO) of India. The drug can be used in the treatment of fungal infections including mucormycosis infections.
2020: Pfizer Inc. in association with its partner Basilea Pharmaceutica Ltd., launched Cresemba (isavuconazole). The drug is used in mucormycosis and invasive aspergillosis.
September 2019: U.S. FDA granted Fast Track designations for intravenous (IV) and oral formulations for fosmanogepix (APX001) developed, by Amplyx Pharmaceuticals.
The report analyses the mucormycosis market based on species, diagnosis method, drugs, distribution channel and country. Various species of fungi covered in mucormycosis market are rhizopus, cuninghamella, rhizomucor, saksenaea, apophysomyces, lichtheimia, mucor and other. By diagnosis method, the market is segmented into the magnetic resonance imaging, computed tomography, tissue biopsy and other. Based on drugs the market is segmented into Amphotericin B, isavuconazole, Posaconazole, voriconazole, flucytosine, fluconazole and other drugs. Based on distribution channel, the market is segmented into the hospital pharmacies, retail pharmacies and online pharmacies. The report also analyses the impact of COVID-19 on the market and it concludes that the COVID-19 has almost affected every market is healthcare industries positively or negatively. The mucormycosis market is primarily driven by the emergence of COVID-19 pandemics. Before the pandemic situation, the fungal infection is rare but COVID-19 is causing high healthcare challenges across the globe. The increasing cases of COVID-19 will significantly increase the number of mucormycosis cases across the globe. The report also comprised of major key players operating in the market.
Why to buy this report
